In silico detection of potential prognostic circRNAs through a re‑annotation strategy in ovarian cancer

Guo,Qiuyan; He,Yanan; Sun,Liyuan; Kong,Congcong; Cheng,Yan; Zhang,Guangmei

doi:10.3892/ol.2019.10021

In silico detection of potential prognostic circRNAs through a re‑annotation strategy in ovarian cancer

Authors:
- Qiuyan Guo
- Yanan He
- Liyuan Sun
- Congcong Kong
- Yan Cheng
- Guangmei Zhang
View Affiliations

Affiliations: Department of Gynecology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
Published online on: February 6, 2019 https://doi.org/10.3892/ol.2019.10021
Pages: 3677-3686
Copyright: © Guo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer (OC) is the most common and lethal gynecologic malignancy. The pathophysiology of OC tumor development is complex and involves numerous biological pathways. Previous studies suggest that circular (circ)RNAs serve important roles in OC tumor pathology. In the present study, a re‑annotation strategy was performed to evaluate the expression level of circRNAs based on a microarray dataset obtained from the Gene Expression Omnibus database. Univariate and multivariate Cox regression analyses were performed to evaluate the association between survival and expression of circRNAs in each OC cohort. An expression‑based risk score model was constructed to extrapolate the prognostic efficacy of this signature. In the GSE9891 dataset, the 278 OC patients were randomly divided into training and validating groups. A six‑circRNA signature was significantly associated with overall survival in the training and validating datasets. The risk score model was further validated in GSE63885 and GSE26193 datasets. The six‑circRNA signature was also significantly associated with patient progression‑free survival and disease‑free survival. Further investigation revealed that the signature had higher area under the curve values than the existing clinical and other molecular signatures in predicting survival. In conclusion, the present study revealed that the six‑circRNA signature may serve as a potential prognostic biomarker of OC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Rustin G, van der Burg M, Griffin C, Qian W and Swart AM: Early versus delayed treatment of relapsed ovarian cancer. Lancet. 377:380–381. 2011. View Article : Google Scholar : PubMed/NCBI
3	Bowtell DD: The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer. 10:803–808. 2010. View Article : Google Scholar : PubMed/NCBI
4	Li C, Bonazzoli E, Bellone S, Choi J, Dong W, Menderes G, Altwerger G, Han C, Manzano A, Bianchi A, et al: Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. Proc Natl Acad Sci USA. 116:619–624. 2019. View Article : Google Scholar : PubMed/NCBI
5	Kumar L, Shamsuzzam A, Haque R, Baghel T and Nazir A: Circular RNAs: The emerging class of non-coding RNAs and their potential role in human neurodegenerative diseases. Mol Neurobiol. 54:7224–7234. 2017. View Article : Google Scholar : PubMed/NCBI
6	Chen LL: The biogenesis and emerging roles of circular RNAs. Nat Rev Mol Cell Biol. 17:205–211. 2016. View Article : Google Scholar : PubMed/NCBI
7	Shang Q, Yang Z, Jia R and Ge S: The novel roles of circRNAs in human cancer. Mol Cancer. 18:62019. View Article : Google Scholar : PubMed/NCBI
8	Chekulaeva M and Rajewsky N: Roles of long noncoding RNAs and circular RNAs in translation. Cold Spring Harb Perspect Biol. a0326802018. View Article : Google Scholar : PubMed/NCBI
9	Wilusz JE and Sharp PA: Molecular biology. A circuitous route to noncoding RNA. Science. 340:440–441. 2013. View Article : Google Scholar : PubMed/NCBI
10	Hansen TB, Kjems J and Damgaard CK: Circular RNA and miR-7 in cancer. Cancer Res. 73:5609–5612. 2013. View Article : Google Scholar : PubMed/NCBI
11	Li Y, Zheng Q, Bao C, Li S, Guo W, Zhao J, Chen D, Gu J, He X and Huang S: Circular RNA is enriched and stable in exosomes: A promising biomarker for cancer diagnosis. Cell Res. 25:981–984. 2015. View Article : Google Scholar : PubMed/NCBI
12	Zheng Q, Bao C, Guo W, Li S, Chen J, Chen B, Luo Y, Lyu D, Li Y, Shi G, et al: Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs. Nat Commun. 7:112152016. View Article : Google Scholar : PubMed/NCBI
13	Du Z, Fei T, Verhaak RG, Su Z, Zhang Y, Brown M, Chen Y and Liu XS: Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer. Nat Struct Mol Biol. 20:908–913. 2013. View Article : Google Scholar : PubMed/NCBI
14	Glazar P, Papavasileiou P and Rajewsky N: circBase: A database for circular RNAs. RNA. 20:1666–1670. 2014. View Article : Google Scholar : PubMed/NCBI
15	Jiang H and Wong WH: SeqMap: Mapping massive amount of oligonucleotides to the genome. Bioinformatics. 24:2395–2396. 2008. View Article : Google Scholar : PubMed/NCBI
16	Ishwaran H and Kogalur UB: Consistency of random survival forests. Stat Probab Lett. 80:1056–1064. 2010. View Article : Google Scholar : PubMed/NCBI
17	Zhan X, Dong C, Liu G, Li Y and Liu L: Panel of seven long noncoding RNA as a candidate prognostic biomarker for ovarian cancer. Onco Targets Ther. 10:2805–2813. 2017. View Article : Google Scholar : PubMed/NCBI
18	Yu G, Wang LG, Han Y and He QY: clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
19	Zhou M, Sun Y, Sun Y, Xu W, Zhang Z, Zhao H, Zhong Z and Sun J: Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer. Oncotarget. 7:32433–32448. 2016.PubMed/NCBI
20	Li ZC, Huang MH, Zhong WQ, Liu ZQ, Xie Y, Dai Z and Zou XY: Identification of drug-target interaction from interactome network with ‘guilt-by-association’ principle and topology features. Bioinformatics. 32:1057–1064. 2016. View Article : Google Scholar : PubMed/NCBI
21	Wilkerson MD and Hayes DN: ConsensusClusterPlus: A class discovery tool with confidence assessments and item tracking. Bioinformatics. 26:1572–1573. 2010. View Article : Google Scholar : PubMed/NCBI
22	Panagopoulou M, Karaglani M, Balgkouranidou I, Biziota E, Koukaki T, Karamitrousis E, Nena E, Tsamardinos I, Kolios G, Lianidou E, et al: Circulating cell-free DNA in breast cancer: Size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers. Oncogene. 2019. View Article : Google Scholar : PubMed/NCBI
23	Varkaris A, Katsiampoura A, Davis JS, Shah N, Lam M, Frias RL, Ivan C, Shimizu M, Morris J, Menter D, et al: Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer. Br J Cancer; 2019, View Article : Google Scholar
24	Huelsmann E, Zighelboim I, Ahmed A and Dewdney S: The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: Survey results from members of the society of gynecologic oncologists, a 5-year follow-up. Gynecol Oncol Rep. 20:47–50. 2017. View Article : Google Scholar : PubMed/NCBI